InhibOx has invested in establishing robust and secure processes for building and updating its Scopius database of commercially available and easily synthesized compounds.
InhibOx Ltd (Oxford, UK) and MolPort Ltd (Riga, Latvia) announce a strategic partnership to deliver integration in library design and compound provision.
